Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Haematology and transfusion indexChapter sections
Role and principlesAssessment and patient selectionBaseline assessmentInterventionsMedicines and treatment safetyTargets, monitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook10 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Sickle complications, transfusion and infection prevention

Haematology and transfusion · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Time-critical presentation

Fever in functional asplenia, new focal neurology, or post-transfusion pain, jaundice and haemoglobin below the pre-transfusion value needs immediate specialist assessment. Treat suspected sepsis and stroke without waiting for confirmation. Suspected delayed haemolytic transfusion reaction or hyperhaemolysis requires urgent haematology and transfusion-medicine involvement; further red cells can worsen destruction and should be given only for a life-threatening indication under a coordinated plan.

Role and principles

Prevent stroke and invasive infection, prescribe antigen-matched transfusion for defined indications, detect alloimmunisation and iron loading, and recognise delayed haemolytic and hyperhaemolysis reactions.

Sickle prevention targets predictable vulnerabilities. Splenic dysfunction appears early, impairing clearance of encapsulated organisms. National immunisation schedules, additional risk-group vaccines, prescribed penicillin prophylaxis and a written fever plan reduce mortality. Before travel, review malaria, meningococcal and destination-specific risks. No preventive layer makes fever safe to watch. Sepsis signs may initially be subtle, and empirical antibiotics should follow the local asplenia or sickle pathway after cultures when feasible.

Transfusion changes circulating biology immediately. A simple transfusion improves oxygen carriage but also raises viscosity, particularly when baseline haemoglobin is relatively high. Exchange replaces sickling cells while controlling volume and haematocrit. Product selection matters because people with sickle-cell disease have high alloimmunisation risk from antigen mismatch, variant Rh alleles and repeated exposure. Historical antibodies remain relevant after titres wane. A shared transfusion passport and early communication with the laboratory prevent dangerous rediscovery during emergencies.

Assessment and patient selection

Invasive infection

Fever, rigors, reduced alertness or poor perfusion in functional asplenia needs immediate antibiotics even when vaccinations and prophylaxis are current.

Acute stroke

Facial asymmetry, weakness, speech change, seizure or altered consciousness triggers hyperacute imaging and urgent exchange-transfusion discussion.

Delayed haemolysis

Pain, fever, jaundice, haemoglobinuria and an unexpected haemoglobin fall one to three weeks after transfusion may mimic crisis.

Hyperhaemolysis emergencyRed flag

Haemoglobin below the pre-transfusion baseline with haemolysis and reticulocyte suppression or rise requires urgent specialist management before more blood.

Iron organ injury

Rising liver iron, hepatic dysfunction, endocrine disturbance or cardiac iron indicates cumulative burden not reliably quantified by one ferritin.

Baseline assessment

  1. 01
    Transcranial Doppler ultrasonographyFirst step
    Why
    Stratify primary stroke risk in children with sickle-cell anaemia.
    Interpretation and limitations
    Abnormal results are repeated or confirmed and acted on through the national protocol; transfusion reduces risk while maintaining specified haemoglobin S targets.
  2. 02
    Extended red-cell genotype or phenotype
    Why
    Guide antigen matching before repeated exposure.
    Interpretation and limitations
    Genotype can resolve recent-transfusion mixtures and Rh variants; results and historical antibodies should be permanently accessible to laboratories.
  3. 03
    Antibody screen and direct antiglobulin test
    Why
    Investigate compatibility and a suspected haemolytic reaction.
    Interpretation and limitations
    New alloantibodies may be delayed or undetectable and a negative screen does not exclude delayed haemolysis or hyperhaemolysis.
  4. 04
    Haemoglobin, reticulocytes, bilirubin and LDH
    Why
    Quantify post-transfusion red-cell survival and marrow response.
    Interpretation and limitations
    A fall below baseline with haemolysis is particularly concerning; compare pre- and post-transfusion values and haemoglobin fractions.
  5. 05
    Haemoglobin S fraction

Interventions

01Before exposureBuild a transfusion identityFirst stepSickle-cell disease is diagnosed or a first planned transfusion approaches.+
  1. 1Obtain extended antigen phenotype or genotype before transfusion where possible and retrieve records from every previous transfusion provider.
  2. 2Record all current and historical alloantibodies and issue a patient-held transfusion alert linked to the haemoglobinopathy network.
  3. 3Request BSH-standard sickle-compatible antigen matching and select simple or exchange technique from indication, baseline haemoglobin, urgency and iron burden.
02Stroke preventionAct on vascular risk before symptomsA child enters the age-defined transcranial Doppler surveillance programme.+
  1. 1Perform studies in an accredited pathway and repeat inadequate, conditional or abnormal examinations at the specified interval.

Medicines and treatment safety

Reduces invasive pneumococcal risk as part of layered prevention in functional hyposplenism.

Phenoxymethylpenicillin

Follow the current sickle and asplenia protocol, commonly 250 mg orally twice daily in adults for ongoing prophylaxis, with macrolide or other local alternative for genuine allergy.

Breakthrough sepsis remains possible; check adherence, allergy accuracy and local resistance advice and ensure fever triggers immediate hospital treatment rather than extra prophylactic doses.

Provides once-daily oral iron chelation for sustained transfusional loading.

Deferasirox

For transfusional overload, a common film-coated-tablet starting dose is 14 mg/kg orally once daily; adjust in 3.5–7 mg/kg steps to transfusion rate, ferritin trend and MRI tissue iron. Dispersible tablets use different strengths and must not be interchanged dose for dose.

Check creatinine and eGFR in duplicate before treatment and monitor renal, urinary protein and liver indices closely; gastrointestinal bleeding, cytopenia and dehydration-related kidney injury require interruption or review. Avoid basing treatment on one inflammatory ferritin.

Oral chelation can be useful when other treatment is inadequate and is particularly considered in cardiac iron strategies.

Deferiprone

A usual adult total is 75 mg/kg/day orally in 3 divided doses, with a licensed maximum of 100 mg/kg/day; the haemoglobinopathy service may combine it with another chelator for severe cardiac iron.

Check neutrophils weekly during the first year; after an uninterrupted stable year, a specialist may align monitoring with transfusion every 2–4 weeks. Stop immediately for fever, sore throat or other infection symptoms, obtain an urgent count and

Targets, monitoring and follow-up

  • On chronic transfusion measure pre-transfusion haemoglobin, haemoglobin S fraction, interval symptoms and antibody screen against the programme target.
  • Maintain an accessible lifetime antibody and reaction record and verify it before every elective or emergency component request.
  • Trend ferritin and transfusion iron input and obtain organ MRI at specialist intervals rather than waiting for overt liver or cardiac disease.
  • During chelation monitor product-specific renal, liver, full-count, hearing, vision and gastrointestinal safety and assess adherence without blame.
  • Audit transcranial Doppler attendance, result quality and timely action on abnormal studies through the paediatric haemoglobinopathy network.
  • At routine contacts confirm vaccines, antimicrobial supply, fever knowledge, travel planning and the correct emergency contact route.

Special situations

Old antibodies still matter

Alloantibody titres may become undetectable, but re-exposure can provoke an anamnestic delayed haemolytic reaction.

Exchange controls two variables

It lowers haemoglobin S while limiting total haematocrit and net iron, making it distinct from simply giving more cells.

Pain can be a reaction

Post-transfusion haemolysis often resembles vaso-occlusive pain; timing and comparison with the pre-transfusion haemoglobin expose the difference.

Prevention remains layered

Vaccination, penicillin and urgent antibiotic access each cover gaps left by the others in functional asplenia.

Common pitfalls

  1. 01

    Ignoring antibodies that are no longer detectable.

  2. 02

    Transfusing uncomplicated pain without another indication.

  3. 03

    Using one ferritin to diagnose organ iron loading.

  4. 04

    Giving further blood reflexively during possible hyperhaemolysis.

  5. 05

    Assuming vaccinated patients cannot develop pneumococcal sepsis.

  6. 06

    Missing an abnormal transcranial Doppler follow-up.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Haematology and transfusionOriginal SBA

Post-transfusion haemoglobin fall

Ten days after transfusion, a patient with sickle-cell disease develops severe pain, jaundice and haemoglobin below the pre-transfusion value. What is the safest interpretation and action?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Haematology and transfusion topics →
Sources and review status6 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • British Society for Haematology sickle transfusion principlesAntigen matching, antibody history, component specification and reaction investigation.
  • British Society for Haematology transfusion indicationsAcute, chronic, peri-operative and stroke-prevention indications.
  • British Society for Haematology iron-overload guidelineChelator selection, ferritin and MRI interpretation, organ surveillance and toxicity monitoring.
  • BNF iron-chelator monographsUK deferasirox dosing and safety, cross-checked with the BNF monographs for deferiprone and desferrioxamine.
  • UKHSA Green Book immunisation guidanceVaccination of people with absent or dysfunctional spleen.
  • NHS Sickle Cell and Thalassaemia screening handbookNational newborn, antenatal and paediatric pathway standards including stroke-risk follow-up.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. ·

Stroke prevention illustrates protocolised transfusion benefit. Children with confirmed abnormal transcranial Doppler velocities begin regular transfusion under the specialist pathway to suppress haemoglobin S. Secondary prevention after overt stroke usually also involves long-term transfusion, alongside neurorehabilitation and vascular assessment. Chronic exposure brings iron loading, access complications, reactions and alloantibodies, so exchange and chelation strategies are reviewed. Delayed haemolysis requires special caution: pain can be mistaken for vaso-occlusion, yet further transfusion may intensify hyperhaemolysis.

Key points

  • Functional hyposplenism makes encapsulated bacterial infection a lifelong risk; vaccination, antimicrobial prophylaxis and rapid empirical treatment are complementary layers, not substitutes.
  • Children enter a transcranial Doppler programme because persistently abnormal cerebral arterial velocities identify a group that benefits from regular transfusion for primary stroke prevention.
  • A new neurological deficit activates the hyperacute stroke pathway and urgent sickle transfusion discussion; a normal initial CT does not exclude ischaemic stroke.
  • Transfusion indications include stroke prevention, severe acute chest syndrome and selected peri-operative or organ-threatening complications, not uncomplicated pain or steady-state anaemia alone.
  • Before transfusion, retrieve the complete antibody history and use ABO-compatible, Rh- and Kell-matched, haemoglobin S-negative units with extended matching according to BSH guidance and individual antibodies.
  • Genotyping is valuable when recent transfusion or variant Rh expression makes serological phenotype unreliable, and the result should be shared across transfusion networks.
  • Simple transfusion raises haemoglobin but adds viscosity and iron; exchange lowers haemoglobin S while limiting net iron and can suit severe or long-term indications.
  • Delayed haemolytic reaction may appear days to weeks later with pain, jaundice, dark urine and falling haemoglobin; a current antibody screen can be negative.
  • Hyperhaemolysis destroys transfused and autologous cells, sometimes lowering haemoglobin below baseline; avoid reflex further transfusion while specialist immune treatment is organised.
  • Chronic programmes require ferritin trends, liver iron MRI where indicated, chelation adherence review, vascular-access planning and repeated consent around burden and alternatives.
Why
Measure effectiveness of chronic or exchange transfusion.
Interpretation and limitations
Interpret with total haemoglobin, timing and programme target; a low percentage does not remove viscosity or reaction risk.
  • 06
    Ferritin and liver iron MRI
    Why
    Assess cumulative transfusional iron burden.
    Interpretation and limitations
    Ferritin varies with inflammation and haemolysis; validated MRI better quantifies tissue iron when chronic exposure or trends justify it.
  • 07
    Cultures and sepsis testing
    Why
    Identify infection in a febrile hyposplenic patient.
    Interpretation and limitations
    Blood cultures and source tests guide refinement, but antibiotic delivery cannot await results in systemic illness.
    • 2
    For confirmed abnormal velocity, organise regular transfusion to maintain haemoglobin S below 30%, with iron monitoring and chelation or exchange planning, rather than relying on antiplatelet treatment.
  • 3For any acute neurological symptom activate stroke imaging and exchange discussion immediately, then establish secondary prevention and rehabilitation after diagnosis.
    • 03Post-transfusion declineDistinguish reaction from recurrent crisisPain, dark urine, fever or anaemia develops days to weeks after red-cell exposure.+
    1. 1Contact haematology and transfusion medicine, compare haemoglobin with pre-transfusion baseline and send haemolysis, reticulocyte, antibody and haemoglobin-fraction studies.
    2. 2Avoid non-essential further transfusion when delayed reaction or hyperhaemolysis is possible; if anaemia is life threatening, use a senior agreed antigen and immune-treatment plan.
    3. 3Document the reaction permanently, provide patient-held information and coordinate future matching, pre-transfusion review and disease-modifying alternatives.
    04Infection preventionMake fever action automaticRoutine review, travel planning or a change in vaccine or prophylaxis status occurs.+
    1. 1Reconcile national routine and functional-asplenia vaccines, annual influenza and travel requirements with primary care and the specialist service.
    2. 2AlternativePrescribe indicated penicillin prophylaxis with an allergy alternative and address adherence barriers without implying that tablets replace vaccines.
    3. 3Give explicit instructions and access routes for immediate assessment of fever or systemic illness, including when away from the home hospital.
    do not
    re-challenge after agranulocytosis.
    Parenteral chelation removes iron when oral treatment is unsuitable, insufficient or unsafe.

    Desferrioxamine

    A common chronic regimen is 20–40 mg/kg by subcutaneous infusion over 8–12 hours on 5–7 nights each week; severe cardiac iron may require a specialist continuous intravenous strategy.

    Monitor growth in younger patients, hearing, vision, renal function and infusion sites. Withhold during serious infection, especially suspected Yersinia or mucormycosis, and avoid excessive dosing when tissue iron is low.

    Suppresses immune destruction of autologous and transfused erythrocytes when further transfusion may worsen life-threatening anaemia.

    Immunomodulation for hyperhaemolysis

    Haematology selects intravenous immunoglobulin, corticosteroid and additional rescue therapy using the reaction phenotype and current specialist protocol; there is no safe generic ward regimen.

    Balance infection, thrombosis, fluid and renal risk; coordinate any unavoidable red-cell exposure with rare-donor and transfusion specialists.

    Report a content problem
    Content changes
    Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom